Invivyd Soars 10.98% on New Measles Antibody Program

On May 13, 2025, Invivyd's stock surged by 10.98% in pre-market trading, marking a significant rise that has caught the attention of investors and analysts alike.

Invivyd has recently announced the launch of a new pipeline discovery program focused on developing a measles-specific monoclonal antibody. This initiative aims to address the limitations of current treatment options, which include high-dose Vitamin A and immune globulin (IG). The program is set to identify a preclinical candidate by the end of 2025, potentially offering a critical therapeutic option for those unable to receive vaccines.

The company's efforts in this area have sparked retail buzz, with investors taking note of Invivyd's commitment to expanding its discovery programs. This new program joins Invivyd's existing initiatives for next-generation COVID-19 and respiratory syncytial virus treatments, further diversifying its pipeline and enhancing its position in the biopharmaceutical sector.